Cellular senescence as endocrine information failure in aging: a review abstract
This abstract describes cellular senescence as distorting hormone communication in aging, with the strongest evidence in pancreatic β-cells and the adrenal zona fasciculata; β-cell senescence is not uniformly harmful, and therapeutic evidence remains mostly preclinical. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract proposes that cellular senescence can distort endocrine communication by changing endocrine-cell identity, stimulus-secretion coupling, secretory timing and local immune or paracrine signaling. [1]
Evidence is described as strongest in pancreatic β-cells and the adrenal zona fasciculata, where composite senescence phenotypes have been linked to endocrine dysfunction and modified by targeted perturbations. [1]
The abstract states that no single marker identifies endocrine senescence across tissues and that therapeutic evidence remains predominantly preclinical. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Endocrine organs and tissues discussed in an aging context, including pancreatic β-cells, the adrenal zona fasciculata, pituitary, thyroid, parathyroid and pineal tissue.
- Summary based on
- Study abstract
- Original publication
- September 8, 2026
Senescence and endocrine signaling in aging
The abstract frames endocrine organs as translating nutrient, stress and circadian cues into hormone outputs that coordinate whole-body physiology. Cellular senescence, it proposes, can distort this communication by changing endocrine-cell identity, stimulus-secretion coupling, secretory timing and local immune or paracrine signaling. This is a conceptual framing in an abstract, not a tested mechanism in a single study.
Supporting source [1]
Strongest evidence in β-cells and adrenal zona fasciculata
Evidence is described as strongest in pancreatic β-cells and the adrenal zona fasciculata, where composite senescence phenotypes have been linked to endocrine dysfunction and modified by targeted perturbations. β-cell senescence is not uniformly deleterious: some states retain insulin production, support functional maturation or restrain immune injury, whereas others propagate inflammatory and paracrine dysfunction. Pituitary and thyroid findings support direct but narrower mechanisms, while parathyroid and pineal evidence remains largely downstream or axis level.
Supporting source [1]
No single marker; preclinical therapeutic evidence
According to the abstract, no single marker identifies endocrine senescence across tissues, and therapeutic evidence remains predominantly preclinical. It calls for a state-resolved approach combining lineage localization, multiple senescence domains and dynamic endocrine readouts to identify pathogenic states and evaluate intervention. These are proposed research directions, not validated clinical tools or treatments.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. It reports no specific study design, sample size, follow-up or effect estimates, and its therapeutic statements are described as predominantly preclinical.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Bi Z, Lin Y. · europepmc.org · September 8, 2026